What Retension Pharmaceuticals Inc.'s executives and directors are doing with their own shares, from SEC Form 3/4/5 filings — separating what the filings state (awards, withholding, disclosed plans) from what only the pattern of dates shows.
| 3 months | 12 months | |
|---|---|---|
| Open-market buys | 2 | 2 |
| Sells | 0 | 0 |
| Total trades | 12 | 12 |
| 3 months | 12 months | |
|---|---|---|
| Acquired | 107,431 | 107,431 |
| Disposed | 0 | 0 |
| Net activity | +107,431 | +107,431 |
View rich charts and dive into the patterns of specific insiders — who is accumulating, who is winding down, and which sale explanations the filings actually support.
| Insider | Relation | Date | Transaction | Shares | Price | Value | Shares held |
|---|---|---|---|---|---|---|---|
| Sweetnam Paul | CHIEF SCIENTIFIC OFFICER | Oct 13 | Derivative Conversion · C | +2,640 | — | — | 2,640 |
| Sweetnam Paul | CHIEF SCIENTIFIC OFFICER | Oct 13 | Derivative Conversion · C | +4,026 | — | — | 406,603 |
| Keller Eric L. | CHIEF EXECUTIVE OFFICER | Oct 13 | Derivative Conversion · C | +31,368 | — | — | 464,407 |
| Keller Eric L. | CHIEF EXECUTIVE OFFICER | Oct 13 | Derivative Conversion · C | +9,662 | — | — | 433,039 |
| Keller Eric L. | CHIEF EXECUTIVE OFFICER | Oct 13 | Open-market buy · P | +20,800 | $12.00 | +$250K | 423,377 |
| Olds Donald | Director | Oct 13 | Derivative Conversion · C | +5,637 | — | — | 5,637 |
| Bisson Sabine | CHIEF OPERATING OFFICER | Oct 13 | Derivative Conversion · C | +2,504 | — | — | 4,115 |
| Bisson Sabine | CHIEF OPERATING OFFICER | Oct 13 | Derivative Conversion · C | +1,611 | — | — | 1,611 |
| Berendt Michael J | Director | Oct 13 | Derivative Conversion · C | +2,640 | — | — | 6,666 |
| Berendt Michael J | Director | Oct 13 | Derivative Conversion · C | +4,026 | — | — | 4,026 |
| Berger Franklin M | Director | Oct 13 | Open-market buy · P | +10,000 | $12.00 | +$120K | 10,000 |
| Berger Franklin M | Director | Oct 13 | Derivative Conversion · C | +12,517 | — | — | 12,517 |
Loading...
